title: Promising cellular therapeutics for prevention or management of graft-versus-host disease (a review).
abstract: Graft-versus-host disease (GVHD) frequently occurs following allogeneic hematopoietic stem cell transplantation. The primary treatment for GVHD involves immune suppression by glucocorticoids. If patients become refractory to steroids, they have a poor prognosis. Therefore, there is a pressing need for alternative therapies to treat GVHD. Here, we review clinical data which demonstrate that a cellular therapy using mesenchymal stromal cells (MSCs) is safe and effective for GVHD. Since MSCs derived from bone marrow present certain limitations (such as time lag for expansion to clinical dose, expansion failure in vitro, painful and invasive bone marrow MSC isolation procedures), alternative sources of MSCs for cellular therapy are being sought. Here, we review data which support the notion that MSCs derived from Wharton's jelly (WJ) may be a safe and effective cellular therapy for GVHD. Many laboratories have investigated the immune properties of these discarded MSCs with an eye towards their potential use in cellular therapy. We also review data which support the notion that the licensing of MSCs (meaning the activation of MSCs by prior exposure to cytokines such as interferon-γ) may enhance their effectiveness for treatment of GVHD. In conclusion, WJCs can be collected safely and painlessly from individuals at birth, similar to the collection of cord blood, and stored cryogenically for later clinical use. Therefore, WJCs should be tested as a second generation, off-the-shelf cell therapy for the prevention or treatment of immune disorders such as GVHD.
authors.affiliation: Blood and Marrow Transplant Program, University of Kansas Medical Center, KS, USA.
authors.forename: J P
authors.initials: JP
authors.lastname: McGuirk
authors.forename: M L
authors.initials: ML
authors.lastname: Weiss
mesh_terms: D002986:Clinical Trials as Topic; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D007231:Infant, Newborn; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000276:immunology; D011247:Pregnancy; D033581:Stem Cell Transplantation / Q000379:methods*; D014470:Umbilical Cord / Q000166:cytology / Q000276:immunology; D059631:Wharton Jelly / Q000166:cytology / Q000276:immunology